MedPath

Aura Biosciences to Present New Phase 1 Data for Bel-sar in Bladder Cancer at EAU 2025

• Aura Biosciences will present additional Phase 1 clinical data for bel-sar in non-muscle invasive bladder cancer at the upcoming European Association of Urology Congress in Madrid.

• The presentation will showcase the latest findings on bel-sar, a novel therapeutic candidate being evaluated for patients with non-muscle invasive bladder cancer.

• The company will also participate in the EAU Research Forum, providing an opportunity to engage with leading urological researchers and clinicians.

Aura Biosciences is set to unveil new Phase 1 clinical trial data for their investigational therapy bel-sar in the treatment of non-muscle invasive bladder cancer (NMIBC). The data presentation will take place at the prestigious 40th Annual European Association of Urology (EAU) Congress, scheduled for March 21-24, 2025, in Madrid, Spain.

Clinical Development Progress

The presentation represents an important milestone in the development of bel-sar, as researchers continue to evaluate its potential as a new treatment option for patients with NMIBC. The Phase 1 trial is designed to assess the safety and preliminary efficacy of bel-sar in this patient population, where new therapeutic options are urgently needed.

Scientific Exchange and Collaboration

Beyond the data presentation, Aura Biosciences will actively participate in the EAU Research Forum during the congress. This engagement provides a valuable platform for scientific exchange with leading experts in the field of urology and offers opportunities for collaboration and discussion of the latest advances in bladder cancer treatment.

Strategic Implications

The presentation at the EAU Congress, one of the most significant gatherings in the urological community, underscores Aura Biosciences' commitment to advancing innovative treatments for urological cancers. The additional Phase 1 data will help inform the future development pathway for bel-sar and potentially shape new treatment strategies for patients with non-muscle invasive bladder cancer.
The upcoming presentation is particularly significant given the current treatment landscape for NMIBC, where there remains a substantial need for more effective and well-tolerated therapeutic options. The results from this Phase 1 study could provide important insights into bel-sar's potential role in addressing this unmet medical need.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Palazestrant Plus Ribociclib Shows Promise in Advanced Breast Cancer

Palazestrant combined with ribociclib demonstrates encouraging clinical activity in ER+/HER2- advanced or metastatic breast cancer patients, including those with ESR1 mutations.
The combination therapy shows a favorable safety profile, consistent with ribociclib, and is well-tolerated, supporting its potential as a first-line treatment option.

Puma Biotechnology Initiates Phase 2 Trial of Alisertib for HR+/HER2- Metastatic Breast Cancer

Puma Biotechnology has started the ALISCA-Breast1, a Phase 2 clinical trial, to evaluate alisertib plus endocrine therapy for HR-positive, HER2-negative metastatic breast cancer.
The trial aims to determine the optimal dose of alisertib in combination with endocrine therapy, assessing objective response rate, duration of response, and progression-free survival.

Aura Biosciences Advances Bel-Sar in Multiple Clinical Trials for Ocular and Bladder Cancers

Aura Biosciences reports progress in Phase 3 trial for choroidal melanoma with bel-sar, showing an 80% tumor control rate in Phase 2 among Phase 3-eligible patients.
The company is expanding bel-sar's development into bladder cancer, with a Phase 1 trial underway for non-muscle invasive and muscle invasive bladder cancer.

Aura Biosciences' Bel-sar Shows Promise in Choroidal Melanoma and Bladder Cancer Trials

Aura Biosciences reports positive Phase 2 data for bel-sar in early-stage choroidal melanoma, demonstrating 80% tumor control and 90% visual acuity preservation.
Phase 1 trial of bel-sar in NMIBC shows clinical complete response in low-grade disease and immune activation, suggesting potential as a novel immune-ablative treatment.

Erasca's Naporafenib Shows Promise in NRAS-Mutant Melanoma, RAS Targeting Franchise Advances

Erasca's Naporafenib, combined with trametinib, demonstrates potential for durable efficacy in NRAS-mutant melanoma, addressing a critical unmet need after frontline immunotherapy.
Phase 1b SEACRAFT-1 trial data supports a tissue-specific approach, reducing dermatologic toxicities through mandatory primary prophylaxis, reinforcing the ongoing Phase 3 SEACRAFT-2 trial.

Erasca's Naporafenib Shows Promise in NRAS-Mutant Melanoma, RAS Targeting Programs Advance

Erasca's naporafenib plus trametinib demonstrates a 40% response rate in NRAS-mutant melanoma patients in the Phase 1b SEACRAFT-1 trial.
The Phase 3 SEACRAFT-2 trial is progressing with randomized data expected in 2025, supported by regulatory alignment in the US and Europe.

Belzupacap Sarotalocan Shows Promise in Early-Stage Bladder Cancer Trial

Belzupacap sarotalocan (bel-sar) demonstrates encouraging clinical activity and a favorable safety profile in patients with non-muscle-invasive bladder cancer (NMIBC) in an ongoing phase 1 trial.
In low-grade NMIBC patients treated with light-activated bel-sar, 4 of 5 achieved a complete clinical response, showing no tumor cells detected post-treatment.

Bayer Seeks EU Approval for Nubeqa in Metastatic Hormone-Sensitive Prostate Cancer

Bayer has submitted an application to the European Union for approval of Nubeqa (darolutamide) for metastatic hormone-sensitive prostate cancer (mHSPC).
The application is based on Phase III ARANOTE trial data, which demonstrated a significant extension in radiographic progression-free survival (rPFS) when Nubeqa was combined with hormone therapy.

Nxera and Cancer Research UK Presenting Phase 1/2a Trial of EP4 Antagonist HTL0039732 at ESMO 2024

Nxera Pharma and Cancer Research UK are presenting the Phase 1/2a trial of HTL0039732, an oral EP4 antagonist, at ESMO 2024, highlighting its potential in treating advanced solid tumors.
The trial evaluates HTL0039732's safety, tolerability, and anti-tumor activity as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors.

Aura Biosciences' Bel-Sar Shows Promise in Phase 2 for Early-Stage Choroidal Melanoma

Bel-sar (AU-011) demonstrated an 80% tumor control rate in Phase 2 trial participants with early-stage choroidal melanoma.
The study showed a 90% visual acuity preservation rate among patients treated with bel-sar, offering a vision-sparing alternative to radiation.

Reference News

[1]
Aura Biosciences announces additional Phase 1 data on bel-sar
markets.businessinsider.com · Mar 3, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy